AstraZeneca Starts Phase 1 of Antibodies That Could Protect Against COVID-19 for 6 Months - COVID-19 Clinical Trial
Breaking News | COVID-19

AstraZeneca Starts Phase 1 of Antibodies That Could Protect Against COVID-19 for 6 Months

AstraZeneca has started a phase 1 clinical trial of its two-antibody cocktail against COVID-19. The 48-subject trial is set to deliver data later this year and set AstraZeneca up to evaluate the protective and therapeutic effect of the drug in larger phase 2 and 3 studies.

In the trial, AstraZeneca will test multiple intramuscular and intravenous doses of the drug, AZD7442, and a placebo in healthy adults. The trial is primarily designed to gather safety data. Subjects will stay at the clinical research unit for at least 24 hours after receiving AZD7442 and continue to be tracked for about one year after they are discharged. 

AstraZeneca will share data from the trial well before the end of the follow-up period. As it stands, AstraZeneca expects to share data before the end of the year. The readout will inform AstraZeneca’s plans for phase 2 and 3 development of AZD7442.


AstraZeneca Ropes in Catalent Gene Therapy for Vaccine

In the hunt for a novel coronavirus vaccine, British drugmaker AstraZeneca has raced to the front of the pack with promising interim data and a slew of proposed supply deals. One of its earliest partners in the effort, New Jersey CDMO Catalent, is now adding to its responsibilities as the vaccine nears regulatory scrutiny.

AstraZeneca and Catalent have fleshed out their manufacturing deal for the University of Oxford’s adenovirus-based COVID-19 vaccine to include drug substance production, including viral vectors, at the CDMO’s gene therapy facility in Harmans, Maryland, the partners said Monday.

Catalent will start production there in the third quarter, building on its previous pact with AstraZeneca for fill-finish and packaging duties at its Anagni, Italy, site.The Harmans facility is in the vicinity of the Baltimore/Washington International Thurgood Marshall Airport—nearby air transport is common among commercial gene therapy manufacturing sites—and includes 20,000 square feet of commercial and clinical capacity. The facility is one of five gene therapy sites Catalent operates in Maryland and holds multiple CGMP manufacturing suites, including fill-finish, testing, warehousing and supply chain capabilities.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.